BRIEF—Innate Pharma gears up for Lumoxiti launch

Paris-based Innate Pharma has appointed Jennifer Butler as general manager of its American unit, Innate Pharma US, leading corporate activities to commercialize the novel leukemia therapy Lumoxiti (moxetumomab pasudotox-tdfk).

Ms Butler leaves Tessa Therapeutics, where she served as chief business officer and chief commercial officer. She previously led the product launch of Imfinzi (durvalumab) as global commercial head for I-O at AstraZeneca.

Ms Butler will also collaborate with Innate’s global commercial team to support Lumoxiti’s future potential launches in Europe and life cycle management.

Innate has also announced it has appointed Hélène Arditti as a strategic executive advisor for commercialization, and Guillaume Gimonet as senior director, launch excellence for Lumoxiti.